Funding for this research was provided by:
J. Uriach y Compañía, S.A
Received: 20 February 2020
Accepted: 13 April 2020
First Online: 23 April 2020
Ethics approval and consent to participate
: New ethical approval was not required for this analysis of data since previous Ethics Committee approval was obtained for each study and no subject identifying information was disclosed. The studies included complied with the declaration of Helsinki and its revisions, and with the ICH Guidelines on Medicinal products. All participants provided written informed consent.
: Not applicable.
: AV has previously received honoraria for speaking at sponsored meetings from Uriach, GSK, AstraZeneca, Chiesi and Novartis, and is a consultant and grants for research for AstraZeneca, Menarini, Uriach, Novartis, Mylan-MEDA Pharma and Sanofi-Aventis. II is an employee of Uriach. MLK is a member of the International Advisory Board of Rupatadine and received honoraria for lectures from GSK, Astra-Zeneca, Sandoz and TAKEDA. GKS has received research grants from Bayer, Regeneron, GSK and ALK; honoraria for articles, lectures/chairing and advisory boards for AstraZeneca, Brittania Pharmaceuticals, Capnia, Church & Dwight, Circassia, GSK, Uriach, Meda, Merck, MSD, OnoPharmaceuticals, Oxford Therapeutics, Sanofi-Aventis and UCB; travel funding from Bayer and GSK. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva, Uriach, and KYomed-Innov. JM has been a member of national and international scientific advisory boards (consulting), received fees for lectures, and grants for research projects from Allakos, ALK-Abelló, AstraZeneca, Genentech-Roche, Glenmark, GSK, Hartington Pharmaceuticals, Menarini, Mitsubishi-Tanabe, MSD, Mylan-MEDA Pharma, Novartis, Sanofi-Aventis, UCB, and Uriach.